about
Choline Metabolism Alteration: A Focus on Ovarian CancerAfatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerCholine kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.14q32/miRNA clusters loss of heterozygosity in acute lymphoblastic leukemia is associated with up-regulation of BCL11a.
P50
Q26742116-B72F7282-593F-4D55-BDC2-6B627C5DE0FFQ27853078-808715FD-9A94-4040-8F96-4CDFCCE9DDBDQ35027806-23E496FC-55CB-4BA1-B876-9DEE6A1E2BC2Q35659378-5D7B1573-03D0-41E2-B4F0-BB09763FDB06Q37507405-0D5A4F58-AFC6-4563-ADBB-BBAD19FA068DQ38965974-03EA0ED3-3ABE-4804-B6F0-FE8B7C483C8DQ53297840-1AC24F93-AA0C-44B4-8F23-413ACA46EBB0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberta Nicoletti
@ast
Roberta Nicoletti
@en
Roberta Nicoletti
@es
Roberta Nicoletti
@nl
type
label
Roberta Nicoletti
@ast
Roberta Nicoletti
@en
Roberta Nicoletti
@es
Roberta Nicoletti
@nl
prefLabel
Roberta Nicoletti
@ast
Roberta Nicoletti
@en
Roberta Nicoletti
@es
Roberta Nicoletti
@nl
P106
P1153
36448461300
P21
P31
P496
0000-0001-6191-3856